| 000 | 01077 a2200289 4500 | ||
|---|---|---|---|
| 005 | 20250513104910.0 | ||
| 264 | 0 | _c19970129 | |
| 008 | 199701s 0 0 eng d | ||
| 022 | _a0033-3158 | ||
| 024 | 7 |
_a10.1007/BF02245603 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aKapur, S | |
| 245 | 0 | 0 |
_a5-HT2 antagonism and EPS benefits: is there a causal connection? _h[electronic resource] |
| 260 |
_bPsychopharmacology _cMar 1996 |
||
| 300 |
_a35-9 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntipsychotic Agents _xadverse effects |
| 650 | 0 | 4 |
_aBasal Ganglia Diseases _xchemically induced |
| 650 | 0 | 4 |
_aClozapine _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aReceptors, Dopamine D2 _xdrug effects |
| 650 | 0 | 4 |
_aRisperidone _xpharmacology |
| 650 | 0 | 4 |
_aSerotonin Antagonists _xpharmacology |
| 773 | 0 |
_tPsychopharmacology _gvol. 124 _gno. 1-2 _gp. 35-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/BF02245603 _zAvailable from publisher's website |
| 999 |
_c8928206 _d8928206 |
||